Depression Therapy With Party-Drug Roots Faces FDA Panel Review

(Bloomberg) -- Potential for abuse and strategies for containing any risks from an experimental depression treatment from Johnson & Johnson will be in focus at an Food and Drug Administration panel...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.